ArticleClinical kidney journal2026
Differing effects of Nefecon and Sparsentan in a patient with recurrent IgA nephropathy post-kidney transplantation.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is a major cause of late graft loss after kidney transplantation, yet evidence for newly approved IgAN-specific therapies in this setting is scarce. We report a young male transplant recipient with biopsy-proven recurrent IgAN 7 years after living-donor transplantation. Treatment with targeted-release budesonide (Nefecon) was associated with a delayed and incomplete antiproteinuric response, clinically relevant systemic glucocorticoid-related adverse effects and progressive graft function decline. After discontinuation of Nefecon, combined therapy with Sparsentan and empagliflozin resulted in sustained albuminuria reduction, stabilization of graft function, improved blood pressure control, and resolution of metabolic complications. This case highlights challenges and opportunities in integrating novel IgAN therapies into post-transplant care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.